Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KRINTAFEL vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
For the radical cure of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
Adults: 200 mg orally as a single dose.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Primarily metabolized via CYP2D6 to an active metabolite. Tafenoquine itself may also be metabolized by monoamine oxidase (MAO).
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
≥99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
Approximately 10-15 L/kg, indicating extensive tissue distribution and binding to haemoglobin in red blood cells.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral bioavailability is approximately 70-80% under fasting conditions. Food may slightly increase or decrease absorption; however, the label recommends administration with or without food.
Oral: 80-90%.
No adjustment needed for mild to moderate renal impairment (e GFR >=30 m L/min). Not studied in severe renal impairment (e GFR <30 m L/min) or on dialysis; use caution.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
No adjustment for mild Child-Pugh A. Not recommended in moderate (Child-Pugh B) or severe (Child-Pugh C) due to lack of data.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
Children ≥5 years and ≥15 kg: 6 mg/kg (maximum 200 mg) as a single oral dose. Not established for <5 years or <15 kg.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
No specific adjustment; use standard dose with monitoring for adverse effects due to potential age-related renal/hepatic decline.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
Warning: G6PD deficiency – can cause hemolytic anemia in G6PD-deficient individuals. Test for G6PD deficiency before prescribing. Do not use in G6PD-deficient patients.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Hemolytic anemia in G6PD-deficient patients: screen all patients for G6PD deficiency before use.,Methemoglobinemia: monitor for signs; use with caution in patients with NADH-methemoglobin reductase deficiency.,Psychiatric effects: may cause anxiety, depression, or psychosis; use with caution in patients with psychiatric disorders.,Prolonged QT interval: avoid in patients with cardiac conditions or those taking other QT-prolonging drugs.,Hematologic monitoring: monitor CBC during treatment.
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
G6PD deficiency (absolute),History of psychotic disorder (absolute),Breastfeeding (relative; avoid unless infant G6PD normal),Pregnancy (relative; avoid unless benefit outweighs risk)
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Take with food (preferably a fatty meal) to enhance absorption and reduce gastrointestinal side effects. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other specific dietary restrictions.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
No human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
No data on human milk excretion; M/P ratio unknown. Risk to infant cannot be ruled out; consider stopping breastfeeding due to potential adverse effects.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No dose adjustment recommended; pharmacokinetics in pregnancy not studied. Maintain standard dose but use only if clearly needed.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
KRINTAFEL (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Administer with food to improve absorption and reduce gastrointestinal intolerance. Screen patients for G6PD deficiency before use; contraindicated in G6PD-deficient patients due to risk of hemolytic anemia. Monitor for methemoglobinemia, especially in patients with NADH-methemoglobin reductase deficiency. Avoid in pregnancy and lactation unless benefit outweighs risk. Single-dose regimen improves adherence compared to primaquine.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take this medication exactly as prescribed, usually as a single dose with food to reduce stomach upset.,You must be tested for G6PD deficiency before starting this medication; inform your doctor if you have a history of anemia or enzyme deficiency.,Avoid alcohol during treatment as it may increase risk of side effects.,Report any signs of dark urine, yellowing of skin or eyes, unusual tiredness, or shortness of breath immediately.,Do not take this medication if you are pregnant or breastfeeding without consulting your doctor.,This medication cures relapsing malaria; complete the full course even if you feel better.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KRINTAFEL vs ARALEN, answered by our medical review team.
KRINTAFEL is a Antimalarial that works by KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KRINTAFEL and ARALEN depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KRINTAFEL is: Adults: 200 mg orally as a single dose.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KRINTAFEL and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KRINTAFEL is classified as Category C. No human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.